Hexagon Nutrition margins double as clinical nutrition market opens up
Maiden earnings call shows EBITDA margin jumping to 13.83% from 12.33%, as management lays out the structural growth story in fortified foods and therapeutic nutrition.
What's new
- FY26 revenue ₹382.63 cr, up 17.8% YoY; PAT up 56.1% to ₹37.94 cr
- EBITDA margin improved to 13.83% from 12.33% prior year
- Branded segment gross margins at 60-68%; PentaSure brand strong
- Capacity utilization only 30-50% with buffer for tender orders
Themes from the call
Demand
Clinical nutrition TAM of ₹6,300 cr with low penetration offers decades of growth as government fortification and health awareness rise.
Margins
EBITDA margin rose to 13.83% from 12.33% as higher-margin branded sales grew; branded gross margins of 60-68% provide investment headroom.
Capital allocation
No significant capex planned; capacity buffer of 50-70% prioritized for tender-based growth over rapid expansion.
Guidance watch
- Revenue growth maintained at historical 15-20% range for FY27
- EBITDA margin expansion expected directionally, no magnitude quantified
- Capacity utilization to improve to 35-40% blended as order pipeline converts
Risk flags
- Trade receivables spiked to ₹82 cr from ₹60 cr, though cyclical and normalized post Q4
- Tender-based ESG segment creates order lumpiness and working capital swings
- Intense competition from Abbott, Nestle, DSM in clinical nutrition
Key quotes
-
"The market size approximately is 6,300 crores for the clinical nutrition segment. So, we are still a small tip of the iceberg."
— Management, Q&A -
"We are confident of maintaining the growth momentum of 15-20% despite global headwinds."
— Management, Q&A
The brief
Hexagon Nutrition's maiden earnings call as a listed company was clean. FY26 revenue of ₹382.63 cr grew 17.8% and PAT surged 56.1% to ₹37.94 cr. EBITDA margins rose to 13.83% from 12.33% the year before, driven by a richer mix skewed toward the branded segment. The big picture is more interesting. Management put the clinical nutrition market at ₹6,300 cr and described the company as a 'small tip of the iceberg'. That is not pipeline-talk. It is a structural growth story backed by government fortification mandates, rising health awareness, and a shift toward preventive healthcare. The business is diversified across three segments: Branded (30% of revenue, 60-68% gross margins), Premix (40%, 35-40% margins), and ESG/Therapeutic Foods (30%, 25-30% margins). Exports are 50% of revenue, mostly premixes and ESG, with less than 20% exposure to West Asia — a non-trivial hedge against geopolitical risk. Capacity utilization is deliberately low at 30-50% blended. Management keeps buffer for unanticipated tender orders, especially from UN and NGOs in the ESG segment. No significant capex is planned. The working capital spike in Q4 trade receivables to ₹82 cr was cyclical, tied to a large ESG tender dispatch in the last quarter. Revenue growth guidance for FY27 is the same 15-20% range. Further margin gains are expected but not quantified. The real opportunity lies in the branded segment — PentaSure is well established, but Pedia Gold and Obesigo are priority growth brands for tier 2/3 expansion and e-commerce. That is where the 60-68% gross margins generate the funds for reinvestment. The risk is that branded expansion is slow and expensive against deep-pocketed incumbents like Abbott and Nestle. Management's tone is cautiously optimistic, not exuberant. The company is executing well, but the bull case rests on converting the 'tip of the iceberg' into sustained market share gains.
Hexagon Nutrition has the market tailwind. Growing the branded share will determine the multiple.